ABOUT
Val Adams - Pharm.D., FCCP, BCOP
Dr. Adams is on the graduate faculty of the College of Pharmacy and is a member of the Lucille Parker Markey Cancer Center, where he has a clinical practice site. As director of the hematology/oncology residency program, he has trained four residents and maintains an active research lab. Dr. Adams received his bachelor of science degree in pharmacy from the University of Utah and doctor of pharmacy degree from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology/oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship, he joined the University of Kentucky faculty in 1996. Research interests: topoisomerase I inhibitors and topoisomerase expression, chemotherapy-induced toxicity, and supportive care issues, including pain control and nutritional effects on chemotherapy outcomes.
Selected Publications/Presentations
- Case Studies in Colectoral Cancer: Targeting EGFR. Presented at: American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting; 2007 December; Las Vegas, NV
- "An outcomes-based approach to managing antiemetic therapy aided by hand-held computerized methodology: Demonstration of effectiveness using a daily ondansetron-based antiemetic regimen in children. " Holdsworth, M.T., Adams, V.R., Raisch, D.W., Woods, J.G., Winter, S.S. Annals of Pharmacotherapy 2000
- "Pharmacokinetics and Toxicity of Escalating Doses of Melphalan (MEL) Given with Amifostine (AMI) Cytoprotection (CP) in Autologous Hematopoietic Stem Cell Transplantation (AHSCT): A Phase I-II Study. (Meeting abstract)." Adams, V.R., Phillips, G.L., Hale, G.A., Howard, D.S., Munn, R.K., Nath, R., Reece, D.E., Marshall, K.W., Kniska, A., Flomenberg, N. Proc Annu Meet Am Soc Clin Oncol; 19:A920: 2000
- "Malignant lymphomas" Pharmacotherapy a pathophysiologic approach - Chapter 120 (fourth edition) - Adams, V.R., Morris, A.K. - Editors: DiPiro, J.T., Talbert, R.L., Yee, G.R., Matzke, G.R., Posey, L.M., Wells, B.G. Appleton and Lange, Stamford CT, 1999.
- "In vitro evaluation of the ability of L-arginine analogs to inhibit human pancreatic cancer cell growth." Bence, A.K., Adams, V.R., Crooks, P.A.. PharmSci. 1999;1(4): p. S-397.
- "A Novel Approach to Collecting Outcomes Data." Adams, V.R., Jones, K.L. ACCP Annual Meeting. Kansas City, Missouri. November 1999
- "Delayed graft function after renal transplantation." Pfaff, W.W.; Howard, R.J.; Patton, P.R.; Adams, V.R.; Rosen, C.B.; Reed, A. Transplantation 1998 27;65(2):219-23.
- "Cocaine suppresses fetal immune system." Karlix, J.L., Behnke, M., Davis-Eyler, F., Wobie, K., Adams, V., Freiburger, B., Conlon, M., Tebbett,I.R. Pediatr Res. 1998;44:43-6.
- "Metoclopramide inhibits TNF-a induction in human leukocytes stimulated with alloantigens or radiation." Adams, V.R., Tuteja, S., Bryson, J.S. Pharmacotherapy 1998;18:177.
- "The Effect of NAD Status on Chemosensitivity of Human CD34+ Bone Marrow Cells" Adams, V.R., Jacobson, E.L., Vanzant, G. 2nd Annual University of Texas Invitational Oncology Pharmacy Research Conference. Newport Beach, California. February 1998
- "Evaluation of Niacin Status in Whole Blood, CD34+ Cells, and Bone Marrow Cells in Human Cancer Patients" The 12th International Symposium on ADP-Ribosylation Reactions: from Bacterial Pathogenesis to Cancer. Cancun, Mexico. May 1997
- "Comparison of one versus two doses of grapefruit juice on oral cyclosporine pharmacokinetics." Yee, G.C., Adams, V.R., Pessa, L., Braddock, R.J., Ruiz, J., Lowenthal, D.T. Pharmacotherapy 1997;17:1112.
Selected Grants
- PI: Val Adams, Sponsor: Amgen Healthcare Institute, Program: 2008 Pharmacy Residency Stipend Support Program, Title: Oncology Residency, Funding: $40,000
- PI: Val Adams, Sponsor: UNC-Chapel Hill, Program: Subaward, Title: EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer, Funding: $35,030 (renewal)
- Co-I: Val Adams, Sponsor: National Institutes of Health, Title: Synthetic Probes of Protein Prenylation, Funding: $95,710